KLI
LXRX icon

Kelman-Lazarov Inc’s Lexicon Pharmaceuticals LXRX Stock Holding History

Kelman-Lazarov Inc’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-203
Closed -$2.81K – 185
2016
Q4 		$2.81K Hold
203
– – ﹤0.01% 280
2016
Q3 		$3.62K Hold
203
– – ﹤0.01% 326
2016
Q2 		$2.92K Hold
203
– – ﹤0.01% 321
2016
Q1 		$3K Buy
+203
New +$2.13K ﹤0.01% 318

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kelman-Lazarov Inc's LXRX Position: Q1 2017 in Review

Kelman-Lazarov Inc sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 203 shares — an estimated $2.81K sold.

Kelman-Lazarov Inc first reported a position in LXRX in Q1 2016 and held it in 4 quarters. The position peaked at $3.62K in Q3 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

  • Kelman-Lazarov Inc reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 203 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $2.81K.
  • Kelman-Lazarov Inc first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Kelman-Lazarov Inc's Lexicon Pharmaceuticals position peaked at $3.62K in Q3 2016.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on Kelman-Lazarov Inc's 13F filing for Q1 2017, filed 25 Apr 2017.